Emerging frontiers in immuno- and gene therapy for cancer

Authors

Michael P. Gustafson, Immuno-Gene Therapy Committee, International Society for Cell and Gene Therapy; Department of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Phoenix, Arizona, USA.
John A. Ligon, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida, USA.
Alexey Bersenev, Immuno-Gene Therapy Committee, International Society for Cell and Gene Therapy; Department of Laboratory Medicine, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.
Chase D. McCann, Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA; Department of Pediatrics, The George Washington University, Washington, DC, USA.
Nirali N. Shah, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Patrick J. Hanley, Immuno-Gene Therapy Committee, International Society for Cell and Gene Therapy; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA; Department of Pediatrics, The George Washington University, Washington, DC, USA. Electronic address: phanley@childrensnational.org.

Document Type

Journal Article

Publication Date

10-21-2022

Journal

Cytotherapy

DOI

10.1016/j.jcyt.2022.10.002

Keywords

CAR T cell; NK cells; cancer; immunotherapy; point-of-care

Abstract

BACKGROUND AIMS: The field of cell and gene therapy in oncology has moved rapidly since 2017 when the first cell and gene therapies, Kymriah followed by Yescarta, were approved by the Food and Drug Administration in the United States, followed by multiple other countries. Since those approvals, several new products have gone on to receive approval for additional indications. Meanwhile, efforts have been made to target different cancers, improve the logistics of delivery and reduce the cost associated with novel cell and gene therapies. Here, we highlight various cell and gene therapy-related technologies and advances that provide insight into how these new technologies will speed the translation of these therapies into the clinic. CONCLUSIONS: In this review, we provide a broad overview of the current state of cell and gene therapy-based approaches for cancer treatment - discussing various effector cell types and their sources, recent advances in both CAR and non-CAR genetic modifications, and highlighting a few promising approaches for increasing in vivo efficacy and persistence of therapeutic drug products.

APA Citation

Gustafson, Michael P.; Ligon, John A.; Bersenev, Alexey; McCann, Chase D.; Shah, Nirali N.; and Hanley, Patrick J., "Emerging frontiers in immuno- and gene therapy for cancer" (2022). GW Authored Works. Paper 1745.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/1745

Department

Pediatrics